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Research Database to explicate the allocation
of health-care resourcesMore than 99% of the residents in Taiwan have been covered
by National Health Insurance (NHI) since its implementation
in 1995, thanks to the single-payer, universal, and
compulsory policies [1]. To construct and maintain a pub-
licly available database for the purpose of academic
research, the government entrusts the Taiwan National
Health Research Institute (NHRI) to continuously and sys-
temically collect relevant registration and claim data
generated in the insurance system. Therefore, the National
Health Insurance Research Database (NHIRD) contains
comprehensive computerized NHI records of literally the
entire population of Taiwan for the past 2 decades. Under
the “least privilege” principle, qualified researchers are
entitled to access the database after their projects are
reviewed and approved by the NHRI [2]. As a reliable data
source, the NHIRD has facilitated academic research in
various scientific disciplines, and the rapidly increasing
number of research articles is proof of this [3].
In addition to imposing a low barrier for application, the
NHIRD has several advantages that continue to attract in-
vestigators. The almost 100% coverage is an obvious
strength that enables researchers to test their hypotheses
on the scale of a nationwide population. This is a unique
feature that distinguishes the NHIRD from many other
electronic health-care databases, which either register a
specific population (e.g., the Veterans Administration or
Medicare databases from the United States) or comprise
selected samples (e.g., Clinical Practice Research Datalink
from the United Kingdom) [4e6]. Because the NHRI
continuously collects data, and annually updates the
database, investigators are able to longitudinally track a
beneficiary from as early as 1995 to as recent as the pre-
ceding year of study approval. These advantages greatly
enhance statistical power when studying rare diseases or
infrequent outcomes [7]. Moreover, the NHIRD contains
information about every billing order, including details on
service type, claiming doctor (anonymously coded),http://dx.doi.org/10.1016/j.aidm.2015.04.001
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for the Study of the Liver. Published by Elsevier Taiwan LLC. Open accessproduct brand, prescription date, and the cost. Researchers
can figure out where, when, how much, how frequently,
and for how long a patient received a specified intervention
[8]. Even different brands of a generic drug are identifiable
[9]. Another easily overlooked strength of the NHIRD is the
unbiased process of data collection. This merit minimizes
the concern of observer-expectancy effect, given that the
information available is not collected for a specific study.
For investigators’ convenience, the NHRI issues the Longi-
tudinal Health Insurance Database (LHID) as a representa-
tive NHIRD subset. The LHID is composed of details on 1
million individuals randomly sampled from all beneficiaries.
Its representativeness is supported by similar distributions
in age, sex, and health-care cost from the original NHIRD.
However, the NHIRD has crucial limitations that in-
vestigators have to consider when designing their study
[10]. First, it contains little information on data that are
not necessary for reimbursement claims. Lacking exami-
nation results should be recognized as a major weak point.
Similarly, only limited information is available on socio-
economic status, lifestyle, health behavior, or unhealthy
habits. Accordingly, researchers should carefully define the
diseases and outcomes, bearing in mind that the diagnostic
code in the NHIRD is principally meant for billing purposes
and may not be accurate enough by itself. There are
several ways to overcome this limitation. If applicable, the
Registry for Catastrophic Illness Patient Database can be
searched to secure a reliable definition [11]. Entry into this
registry, which waives copayment of the enrollee, is
permitted only after explicit criteria are fulfilled. The pri-
mary diagnoses for hospitalization, particularly those for a
severe illness such as ischemic stroke or acute myocardial
infarction [9,12,13], are also convincing in general. With
regard to outpatient condition or underlying comorbidity,
additional prerequisites other than the diagnostic code can
enhance the reliability. For instance, pharmacotherapy
that defines the diseases is useful [14]. Another major, The Digestive Endoscopy Society of Taiwan and Taiwan Association
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42 Editoriallimitation of the NHIRD is the strict regulations that prohibit
investigators from linking the de-identified database with
external information, for the sake of privacy protection.
Linkage with other public registry databases is possible but
cannot be performed outside the designated offices which
are tightly controlled by the government. Furthermore, the
basic unit that forms the NHIRD is details of an individual
person but without information that can pinpoint kinship or
blood relationship. This is undoubtedly an impassable
obstacle when exploring inheritable traits or household
situations. Finally, the NHIRD includes no data on the self-
pay or trial settings. This limitation, fortunately, is not a
critical issue under most circumstances, because health
services encompassed in the NHI range extensively from
preventive measures to hospice care.
In this issue of the Journal, Yeh and colleagues [15]
added another example to the growing bulk of literature
brought about by analyzing the NHIRD. They utilized data
from LHID (2005), which contains 1 million random samples,
to study the expenditure associated with liver cancer. A
total of 2335 patients with a specific diagnostic code were
identified and their reimbursement claims in 2009 were
analyzed. Perhaps to no one’s surprise, liver cancer pa-
tients utilized more NHI resources compared with those
without the diagnosis, at the ratio of 666.8% for each pa-
tient for the year. The authors also categorized utilization
according to the type of service. Intriguingly, sex, age, in-
come status, residential region, and insured classification
seemed to influence how much a patient was reimbursed.
These investigators are to be commended for reminding us
how liver cancer, most of which is identified as hepato-
cellular carcinoma in histopathologic analysis, has been
financially devastating our country. As a leading cause of
cancer mortality for decades, liver cancer is expensive not
only because of frequent hospital visits, but also because of
the costly services required for diagnosis and treatment.
Given that the incidence of liver cancer remains high and
new therapies keeps hitting the market (e.g., sorafenib was
not covered in Taiwan until 2012), this malignant disease
most likely will continue to take a big bite from the global
budget of NHI.
Yeh et al.’s [15] study, nonetheless, had a few caveats
that warrant attention. The inability to estimate expendi-
ture outside the insurance system is a major limitation.
Conceivably, patients with malignant disease are prone to
seek alternative or folk medicine. In addition, indirect
financial loss was not studied. Another NHIRD-inherent
limitation is the difficulty to ascertain socioeconomic in-
formation. Although their study resorted to insured classi-
fication and premium, the accuracy of these parameters to
stand for income status was not grounded. Moreover, their
investigation was mainly descriptive rather than analytical.
The apparent association of medical expenditure with age,
sex, residential region, and insured classification was
regrettably not further scrutinized. Similarly, the influence
of comorbidity was not addressed. Finally, this study would
have achieved a greater impact if the authors had consid-
ered patient outcomes. Undoubtedly, liver cancer treat-
ment is costly, but what would be more informative is to
elucidate why it is so expensive and how the costs are
associated with clinical outcomes and care quality.The NHIRD is going to deliver more and more research in
the foreseeable future. With such an abundance of claim
data recorded in detail, it provides an appealing venue for
studying health economics, care quality, and cost effec-
tiveness. We now know liver cancer is disproportionately
consuming national health-care resources, and hopefully
we will soon learn more details explicating the expense
allocated to manage this both deadly and costly disease.
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